Loading
Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.
Tissue factor (F3) initiates the extrinsic coagulation cascade; when cancers display it abnormally on their surface it drives thrombosis and angiogenesis, and it becomes an ADC target. It is overexpressed in cervical, pancreatic, head and neck, and ovarian tumours, with 90-95% of cervical and 50-80% of pancreatic cancers positive by IHC. Tisotumab vedotin (Tivdak) is approved in recurrent cervical cancer on the basis of innovaTV 301, and innovaTV did not select patients on tissue factor expression, so the drug is given without a companion test. Topoisomerase-I payload successors (XNW28012) are in phase 3. The open questions are ocular toxicity management and whether newer payloads widen the indication. The simple version is a clotting protein that cancers wear on their surface, letting an ADC find them.
In plain words · Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.
Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.
Initiates the extrinsic coagulation cascade; tumour expression drives thrombosis and angiogenesis.
1 product aims at Tissue factor: antibody-drug conjugates. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Tumour-associated overexpression: 1 cell-killing or cell-finding medicine (Tisotumab vedotin) aim at the antigen, which HPA finds with no normal tissue stained high; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA F3: RNA low tissue specificity; no normal tissue stained high; highest cancer staining skin cancer (7 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Cervical cancer, Pancreatic ductal adenocarcinoma); Open Targets associates it with 1 specific cancer type at or above 0.5 (cervical cancer). (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas F3 tissue; Human Protein Atlas F3 pathology; Open Targets ENSG00000117525 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Scarpati E.M. et al, Biochemistry, 1987, "Human tissue factor: cDNA sequence and chromosome localization of the gene". Source.
What a pathology or genomic report can say about this target, each with the thresholds approvals use.
Initiates the extrinsic coagulation cascade; tumour expression drives thrombosis and angiogenesis.
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
Medium only: breast cancer, carcinoid, liver cancer, melanoma.
HPA F3 tissue · HPA F3 pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Cervical cancer | 90-95% | IHC, any expression | innovaTV did not select on TF | Wikipedia |
| Pancreatic ductal adenocarcinoma | 50-80% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Tisotumab vedotin is an ADC against tissue factor, the first to show a survival benefit in recurrent cervical cancer.
Query for this target: (TITLE:"Tissue factor" OR ABSTRACT:"Tissue factor" OR TITLE:"F3" OR ABSTRACT:"F3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tissue factor, not a curated reading list.
Shares Sutro Biopharma, Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.